100 related articles for article (PubMed ID: 1910891)
21. Mass screening for colorectal cancer: compliance in Almopea Region.
Chrissidis T; Saliangas K; Economou A; Nikoloudis N; Andreadis E; Prodromou K; Georgakis K
Tech Coloproctol; 2004 Nov; 8 Suppl 1():s193-5. PubMed ID: 15655620
[TBL] [Abstract][Full Text] [Related]
22. Colorectal cancer screening compliance by medicine residents: perceived and actual.
Zack DL; DiBaise JK; Quigley EM; Roy HK
Am J Gastroenterol; 2001 Oct; 96(10):3004-8. PubMed ID: 11693339
[TBL] [Abstract][Full Text] [Related]
23. Screen compliance rates in 14-years annual screening program for colorectal cancer with immunochemical fecal occult blood test-- identification of higher priority subjects in health education.
Wei N; Nakama H; Li T
Eur J Med Res; 1998 Jul; 3(7):341-4. PubMed ID: 9682030
[TBL] [Abstract][Full Text] [Related]
24. Colorectal cancer screening by primary care physicians in two medical care organizations.
Hawley ST; Levin B; Vernon SW
Cancer Detect Prev; 2001; 25(3):309-18. PubMed ID: 11425273
[TBL] [Abstract][Full Text] [Related]
25. Is it reasonable to use faecal occult blood test for colorectal cancer screening?
Musil D; Tillich J
Acta Univ Palacki Olomuc Fac Med; 1999; 142():119-21. PubMed ID: 10743740
[TBL] [Abstract][Full Text] [Related]
26. [Physicians' reminders promote annual fecal occult blood testing compliance].
Vinker S; Shumla V; Kitai E
Harefuah; 2000 Jun; 138(12):1019-21, 1088, 1087. PubMed ID: 10979422
[TBL] [Abstract][Full Text] [Related]
27. Primary care patients' understanding of colorectal cancer screening.
Greisinger A; Hawley ST; Bettencourt JL; Perz CA; Vernon SW
Cancer Detect Prev; 2006; 30(1):67-74. PubMed ID: 16458449
[TBL] [Abstract][Full Text] [Related]
28. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
[TBL] [Abstract][Full Text] [Related]
29. Taishotoyama Symposium Barriers to colorectal cancer screening: economics, capacity and adherence.
Inadomi JM
J Gastroenterol Hepatol; 2008 Dec; 23 Suppl 2():S198-204. PubMed ID: 19120898
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing.
Helm JF; Russo MW; Biddle AK; Simpson KN; Ransohoff DF; Sandler RS
Am J Gastroenterol; 2000 Nov; 95(11):3250-8. PubMed ID: 11095350
[TBL] [Abstract][Full Text] [Related]
31. Fecal occult blood testing for colorectal cancer screening: use the finger.
Burke CA; Tadikonda L; Machicao V
Am J Gastroenterol; 2001 Nov; 96(11):3175-7. PubMed ID: 11721767
[TBL] [Abstract][Full Text] [Related]
32. The use of screening colonoscopy for patients cared for by the Department of Veterans Affairs.
El-Serag HB; Petersen L; Hampel H; Richardson P; Cooper G
Arch Intern Med; 2006 Nov; 166(20):2202-8. PubMed ID: 17101937
[TBL] [Abstract][Full Text] [Related]
33. Digital fecal occult blood testing in the ambulatory urology clinic.
Goetzl MA; Outman JE; Griebling TL; Holzbeierlein JM; Weigel JW; Thrasher JB
J Am Coll Surg; 2008 Jan; 206(1):144-7. PubMed ID: 18155580
[TBL] [Abstract][Full Text] [Related]
34. Patterns and predictors of colorectal cancer test use in the adult U.S. population.
Seeff LC; Nadel MR; Klabunde CN; Thompson T; Shapiro JA; Vernon SW; Coates RJ
Cancer; 2004 May; 100(10):2093-103. PubMed ID: 15139050
[TBL] [Abstract][Full Text] [Related]
35. Validation of self-reported colorectal cancer screening behavior from a mixed-mode survey of veterans.
Partin MR; Grill J; Noorbaloochi S; Powell AA; Burgess DJ; Vernon SW; Halek K; Griffin JM; van Ryn M; Fisher DA
Cancer Epidemiol Biomarkers Prev; 2008 Apr; 17(4):768-76. PubMed ID: 18381474
[TBL] [Abstract][Full Text] [Related]
36. Colorectal carcinoma screening procedure use among primary care patients.
Lafata JE; Williams LK; Ben-Menachem T; Moon C; Divine G
Cancer; 2005 Oct; 104(7):1356-61. PubMed ID: 16092119
[TBL] [Abstract][Full Text] [Related]
37. Flexible sigmoidoscopy in the PLCO cancer screening trial: results from the baseline screening examination of a randomized trial.
Weissfeld JL; Schoen RE; Pinsky PF; Bresalier RS; Church T; Yurgalevitch S; Austin JH; Prorok PC; Gohagan JK;
J Natl Cancer Inst; 2005 Jul; 97(13):989-97. PubMed ID: 15998952
[TBL] [Abstract][Full Text] [Related]
38. Fecal occult blood testing: clinical value and limitations.
Simon JB
Gastroenterologist; 1998 Mar; 6(1):66-78. PubMed ID: 9531118
[TBL] [Abstract][Full Text] [Related]
39. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer.
Lindholm E; Brevinge H; Haglind E
Br J Surg; 2008 Aug; 95(8):1029-36. PubMed ID: 18563785
[TBL] [Abstract][Full Text] [Related]
40. Impact of comorbidity on colorectal cancer screening in the veterans healthcare system.
Fisher DA; Galanko J; Dudley TK; Shaheen NJ
Clin Gastroenterol Hepatol; 2007 Aug; 5(8):991-6. PubMed ID: 17627900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
